Ownership and insider activity for PharmaCyte Biotech, Inc. (PMCB): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
PharmaCyte Biotech, Inc. is a biotechnology firm dedicated to the development and commercialization of advanced cellular therapies within the United States. Their primary therapeutic areas include various forms of cancer, diabetes, and malignant ascites. Central to their efforts is Cell-in-a-Box, their proprietary encapsulation technology which utilizes cellulose to enclose live cells.
Price
| Price | $0.42 |
| Market Cap | $4M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-03-31 | WALKER WAYNE REMELL | J-Other | ||
| 2026-03-31 | Abecassis Michael M | J-Other | ||
| 2026-03-31 | SCHECHTER JONATHAN | J-Other | ||
| 2026-03-31 | WEINSTEIN ROBERT | J-Other | ||
| 2026-03-31 | WEINSTEIN ROBERT | A-Award | 119,170 | $80K |
| 2026-03-31 | WALKER WAYNE REMELL | A-Award | 119,170 | $80K |
| 2026-03-31 | SCHECHTER JONATHAN | A-Award | 119,170 | $80K |
| 2026-03-31 | Abecassis Michael M | A-Award | 119,170 | $80K |
| 2026-01-07 | Silverman Joshua | P-Purchase | 40,000 | $33K |
| 2026-01-06 | Silverman Joshua | P-Purchase | 30,000 | $24K |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.5M | $1.1M | $515253 | $894861 | $2.2M | $85.4M | $68.0M | $50.2M | $15.2M | $18.6M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $366316 | $18.5M |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $3.7M | $240766 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $3.5M | $1.3M | $653404 | $1.0M | $2.3M | $85.5M | $68.1M | $50.4M | $22.4M | $37.4M |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $3.5M | $3.5M | $3.5M | $3.5M | $3.5M | $3.5M | $3.5M | $1.5M | $1.5M | 0 |
| Total Assets | $8.7M | $6.4M | $5.8M | $6.2M | $7.4M | $90.6M | $73.3M | $59.9M | $55.2M | $46.8M |
| Accounts Payable | $365600 | $352621 | $121885 | $185842 | $172261 | $205361 | $128281 | $389369 | $399204 | $271102 |
| Short-term Debt | 0 | 0 | 0 | $28918 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $580248 | $644168 | $742851 | $1.0M | $724778 | $704370 | $586581 | $7.4M | $2.9M | $826424 |
| Long-term Debt | 0 | 0 | 0 | $46282 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $580248 | $644168 | $742851 | $1.1M | $724778 | $704370 | $586581 | $20.4M | $3.3M | $11.8M |
| Retained Earnings | -$89.1M | -$96.0M | -$100.0M | -$103.9M | -$107.4M | -$111.6M | -$116.0M | -$115.6M | -$85.0M | -$104.4M |
| Total Equity | $8.1M | $5.8M | $5.0M | $5.1M | $6.7M | $89.9M | $72.7M | $39.5M | $51.9M | $33.3M |
| Total Debt | 0 | 0 | 0 | $75200 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -$3.5M | -$1.1M | -$515253 | -$819661 | -$2.2M | -$85.4M | -$68.0M | -$50.2M | -$15.5M | -$37.1M |
| Working Capital | $3.0M | $639697 | -$89447 | $6248 | $1.6M | $84.8M | $67.6M | $43.0M | $19.5M | $36.6M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 45.28 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -2.67 |
Profitability
| Return on Equity | -50.84% |
| Return on Invested Capital | -14.92% |
| Return on Assets | -41.55% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: BCLI · CYCN · IBO · KTTA · NBY · PLRZ · QNRX
Explore sector: Healthcare · Biotechnology
More sections of PMCB: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks